It is a condition of publication that all manuscripts must be submitted in English to the Toxicon
submission and review website, http://ees.elsevier.com/toxcon/. Authors are requested to transmit the text and art of the
manuscript in electronic form to this address. Each manuscript must also be accompanied by a cover letter outlining the basic findings
of the paper and their significance. The Editors welcome submissions by the authors of the names and addresses of up to five individuals
who could expertly review the paper, and who are not from the same institutions as the authors. The Editors reserve the right to use
these or other reviewers. Should you be unable to provide an electronic version, please contact the editorial office prior to submission
at e-mail: authorsupport@elsevier.com
Submission of a paper implies that it has not been published previously, that
it is not under consideration for publication elsewhere, and that if accepted it will not be published elsewhere in the same form, in
English or in any other language, without the written consent of the publisher. The Editor welcomes submission by the authors of the
names and addresses of up to four or five individuals who could expertly review the submitted manuscripts, and who are not from the same
institutions as the authors. The Editor, of course, reserves the right to use these or other reviewers of his choice.
Language: English is the preferred language, but where submission of a manuscript in English is not possible, French, German
or Spanish can be used as long as the paper is accompanied by a 200-300 word English abstract.
Manuscript Preparation
General: Manuscripts must be typewritten in double-spaced form with wide margins. A font size of 12 or 10 pt is required. Avoid
full justification, (i.e., do not use a constant right-hand margin.) Ensure that each new paragraph is clearly indicated. If possible,
consult a recent issue of the journal to become familiar with layout and conventions. Number all pages and lines consecutively. The
corresponding author should be identified (include a Fax number and E-mail address). Full postal addresses must be given for all co-authors. All numbers should be numbered consecutively. Authors should consult a recent issue of the journal for style if possible. An electronic
copy of the paper should accompany the final version. The Editors reserve the right to adjust style to certain standards of uniformity.
Authors should retain a copy of their manuscript since we cannot accept responsibility for damage or loss of papers. Original manuscripts
are discarded one month after publication unless the Publisher is asked to return original material after use.
Paper length: Toxicon has set no standard length for papers, but the Editors insist upon a clear presentation of data in as concise a form
as is consistent with good reporting. The fragmentation of a report into several short papers is discouraged.
Abstracts: There
should be an abstract of no more than 200 words.
Text: Follow this order when typing manuscripts: Title, Authors, Affiliations,
Abstract, Keywords, Main text (introduction, materials and methods, results and discussions), Acknowledgements, Appendix, References,
Vitae, Figure Captions and then Tables. Do not import the Figures or Tables into your text. The corresponding author should be identified
with an asterisk and footnote. All other footnotes (except for table footnotes) should be identified with superscript Arabic numbers.
Units: Units of measure must be clearly indicated.
Symbols: The Latin name must be given for all animal and plant
species. Trade names or abbreviations of chemicals may be used only when preceded by the chemical or scientific name. Thereafter, trade
names, common names or abbreviations should be used.
Mathematical equations: Compound numbers should be in bold face Arabic
numerals or underscored.
Conflict of interest :Toxicon requires full disclosure of all potential conflicts of interest.
All sources of funding supporting the work are to be declared. At the end of the manuscript text (and in the cover letter of the manuscript),
under a subheading "Conflict of Interest statement", all authors must disclose any financial and personal relationships with other people
or organisations that could inappropriately influence (bias) their work. If there are no conflicts of interest, the authors should state,
"The authors declare that there are no conflicts of interest." Signed copies of the Toxicon Conflict of Interest policy form
are required upon submission. The Conflict of Interest policy form can be downloaded here.
In order to minimize delays, we strongly advise that the signed copies of these statements are prepared before you submit your manuscript.
The corresponding author is responsible for sharing this document with all co-authors. Each and every co-author must sign an individual
disclosure form. The corresponding author is responsible for uploading their form and those of their co-authors.
References:
All publications cited in the text should be presented in a list of references following the text of the manuscript. In the text refer
to the author's name (without initials) and year of publication (e.g. "Since Peterson (1993) has shown that?" or "This is in the agreement
with results obtained later (Kramer, 1994)"). For three or more authors use the first author followed by "et al.", in the text. The list
of references should be arranged alphabetically by authors' names. The manuscript should be carefully checked to ensure that the spelling
of authors' names and dates are exactly the same in the text as in the reference list.
References should be given in the following
form:
Mihelich, E.D., Carlson, D.G., Fox, N., Song, M., Schevitz, R.W., Snyder, D.W., 1997. Structure based design and therapeutic
potential of phospholipase A2 inhibitors. In: Uhl, W., Nevalainen, T.J., Buchler, M.W. (Eds.), Phospholipase A2
Basic and Clinical Aspects in Inflammatory Disease, Karger, Basel, pp. 140-145.
Possani, L.D., 1984. Structure of scorpion toxins.
In: Tu, A.T.T. (Ed.), Handbook of natural toxins, vol. 2. Marcel Dekker, New York, pp. 513-550.
Smith, L.A., 1998. Development of
recombinant vaccines for botulinum neurotoxin. Toxicon 36 (11), 1539-1548.
Illustrations: All illustrations should
be provided in camera-ready form, suitable for reproduction (which may include reduction) without retouching. Photographs, charts and
diagrams are all to be referred to as "Figure(s)" and should be numbered consecutively in the order to which they are referred. They
should accompany the manuscript, but should not be included within the text. All illustrations should be clearly marked on the back with
the figure number and the author's name. All figures are to have a caption. Captions should be supplied on a separate sheet. Line
drawings: Good quality printouts on white paper produced in black ink are required. All lettering, graph lines and points on graphs
should be sufficiently large and bold to permit reproduction when the diagram has been reduced to a size suitable for inclusion in the
journal. Dye-line prints or photocopies are not suitable for reproduction. Do not use any type of shading on computer-generated illustrations. Photographs: Original photographs must be supplied as they are to be reproduced (e.g. black and white or colour). If necessary,
a scale should be marked on the photograph. Please note that photocopies of photographs are not acceptable. Photographs must be kept
to a minimum. Colour: Where colour printing is required the author will be charged for colour printing at the current colour
printing costs.
Tables: Tables should be numbered consecutively and given a suitable caption and each table typed on a separate
sheet. Footnotes to tables should be typed below the table and should be referred to by superscript lowercase letters. No vertical rules
should be used. Tables should not duplicate results presented elsewhere in the manuscript, (e.g. in graphs).
Short Communications:
Short communications differ from full manuscripts only in that the research study does not lend itself to an extended presentation. Even
though brief, the Short communication should represent a complete, coherent and self contained study. The quality of Short Communications
is expected to be as good as that of full articles, and both full articles and Short communications will be refereed in an identical
manner. The form is identical to that for a full article except that the report should not be divided into Introduction, Materials
and Methods, Results and Discussion. An abstract of not more than 75 words should be provided. The Short Communication may not be
longer than five double-spaced typewritten pages (not including references, tables and figures) and should include not more than two
tables of two figures or one of each.
Letters to the Editor: These may be published if judged by the Editor to be of interest
to the broad field of toxinology or of special significance to a smaller group of workers in a specialized field of toxinology. They
should be headed `Letter to the Editor' which should be followed by a title for the communication. Names of authors and affiliations
should be at the end of the letter.
Announcements:Toxicon will only accept for publication announcements of great
interest to toxinologists, such as notices of appropriate meetings and symposia and activities of the International Society of Toxinology.
Reviews: Articles of interest to toxinologists which are published in journals other than Toxicon may be abstracted
in the Reviews section of Toxicon. Readers who feel that a particular article or book should be abstracted in this section are
encouraged to bring their opinions to the attention of the Review Editor.
Molecular Biology: Papers on molecular biological
aspects of toxins are welcome. They can include cloning, expression, genetic and related studies. The papers must add to the understanding
of the role or function of toxins. Papers providing cDNA sequences without any relevant conclusions are not acceptable. If cDNA sequences
are included, authors must guarantee that the sequences will be deposited in a public gene bank before the publication of the paper in Toxicon.
Clinical reports: Toxicon will publish clinical reports on poisoning where a new therapeutic principle has
been proposed or a decidedly superior clinical result has been established. Please observe the following guidelines:
The
title and abstract should include the scientific as well as the local name for the species involved and should provide keywords for indexing
systems, including the country where the envenoming or poisoning occurred and the principal or most important observation.
A
brief description of the responsible organism and, ideally, a photographic record and details of its distinguishing features should be
included. The specimen of the animal or plant should, if possible, be deposited in a recognized museum accessible to scientists from
all over the world.
Clinicians caring for cases of envenoming and poisoning which seem likely to be of interest should save
samples of blood, wound swab or aspirate, stomach contents and urine or, in fatal cases, a block tissue from the site of the bite or
sting for subsequent immunodiagnosis.
Cases of bites by captive species have the advantage that the specimen has often been
identified by the owner, but this identification is sometimes incorrect and in many cases, the precise geographical origin is uncertain.
Independent verification is helpful. Some attempt should be made to investigate the effect of envenoming or poisoning on haematological,
biochemical and other variables measurable in the laboratory.
The clinical description should document the evolution of symptoms,
signs and results or investigations with references to time after bite/sting/ingestion.
The effect of treatment is of great
interest and importance. Details of the manufacturer and specificity of antivenom should be given, and other drugs which may have modified
the clinical presentation and natural history of envenoming or poisoning must be mentioned. The most valuable reports of therapeutic
interventions and the only ones that can be interpreted with confidence are those designed prospectively as randomized, double-blind,
comparative or placebo- controlled trials, in which the numbers of patients chosen for each treatment group are justified by power calculations.
In such cases the keywords 'randomized controlled trial' should be included for indexing purposes. Where possible, objective rather than
subjective assessments of efficacy should be used.
Literature search has now been made easy by CD-ROM and other computerized
systems in most countries. The available literature should be reviewed thoroughly so that repetition of previously published observations
can be avoided and the new observations can be put in context.
Preparation of Supplementary Material
Elsevier
now accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional
possibilities to publish supporting applications, movies, animation sequences, high-resolution images, background datasets, sound clips
and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier web products,
including ScienceDirect (http://www.sciencedirect.com). In order to ensure that your submitted material is directly usable,
please ensure that data is provided in one of our recommended file formats. Files can be stored on diskette, ZIP-disk or CD (either MS-DOS
or Macintosh). Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit http://authors.elsevier.com.
Proofs
Proofs
will be sent to the author (first named author if no corresponding author is identified of multi-authored papers) and should be returned
within 48 hours of receipt. Corrections should be restricted to typesetting errors; any others may be charged to the author. Any queries
should be answered in full. Please note that authors are urged to check their proofs carefully before return, since the inclusion of
late corrections cannot be guaranteed. Proofs are to be returned by email or fax, or to the Log-in Department, Elsevier, Stover Court,
Bampfylde Street, Exeter, Devon EX1 2AH, UK.
Offprints
Additional offprints and copies of the issue can be ordered at
a specially reduced rate using the order form sent to the corresponding author after the manuscript has been accepted.
US National
Institutes of Health (NIH) voluntary posting (" Public Access") policy
Elsevier facilitates author response to the NIH voluntary
posting request (referred to as the NIH "Public Access Policy"; see http://www.nih.gov/about/publicaccess/index.htm) by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author, 12 months after formal publication.
Upon notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com ) that your work has received NIH funding and that you intend to respond to the NIH policy request, along with your NIH award
number to facilitate processing. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version of your manuscript
that will include peer-review comments, for posting 12 months after formal publication. This will ensure that you will have responded
fully to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed Central, and any such posting
is prohibited.
Copyright
All authors must sign the "Transfer of Copyright" agreement before the article can be published.
This transfer agreement enables Elsevier Ltd to protect the copyrighted material for the authors, without the author relinquishing his/her
proprietary rights. The copyright transfer covers the exclusive rights to reproduce and distribute the article, including reprints, photographic
reproductions, microfilm or any other reproductions of a similar nature, and translations. It also includes the right to adapt the article
for use in conjunction with computer systems and programs, including reproduction or publication in machine-readable form and incorporation
in retrieval systems. Authors are responsible for obtaining from the copyright holder permission to reproduce any material for which
copyright already exists.
Author Services
For queries relating to the general submission of manuscripts (including electronic
text and artwork) and the status of accepted manuscripts, please contact Author Services, Log-in Department, Elsevier, The Boulevard,
Langford Lane, Kidlington, Oxford OX5 1GB, UK. E-mail: authors@elsevier.co.uk, Fax: +44 (0) 1865 843905, Tel: +44 (0)
1865 843900. Authors can keep a track of the progress of their accepted article using http://www.elsevier.com/trackarticle
Language Polishing: Authors who require information about language editing and copyediting services pre-and post-submission please
visit http://www.elsevier.com/locate/languagepolishing or contact authorsupport@elsevier.com for more information. Please
note Elsevier neither endorses nor takes responsibility for any products, goods or services offered by outside vendors through our services
or in any advertising. For more information please refer to our Terms & Conditions.
